mk 767 has been researched along with ziprasidone in 1 studies
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (ziprasidone) | Trials (ziprasidone) | Recent Studies (post-2010) (ziprasidone) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 1,068 | 254 | 362 |
| Protein | Taxonomy | mk 767 (IC50) | ziprasidone (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.005 | |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | 5.39 | |
| D | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0004 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2301 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for mk 767 and ziprasidone
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |